(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 September 2025 (12.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/188668 A1

(51) International Patent Classification:
A61K 31/519 (2006.01) *A61K 45/06* (2006.01)
A61K 39/00 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2025/018217

(22) International Filing Date:
03 March 2025 (03.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/561,193 04 March 2024 (04.03.2024) US

(71) Applicant: **FRONTIER MEDICINES CORPORATION** [US/US]; 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US).

(72) Inventors: **WANG, Yan**; c/o Frontier Medicines Corporation, 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US). **WEBSTER, Kevin**; c/o Frontier Medicines Corporation, 151 Oyster Point Blvd., 2nd Floor, South San Francisco, California 94080 (US).

(74) Agent: **DO, Keunbong** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: COMBINATION OF A KRAS G12C INHIBITOR WITH AN IMMUNE CHECKPOINT INHIBITOR FOR THE TREATMENT OF CANCER

(57) Abstract: The present disclosure relates generally to methods for treating cancer with a KRAS inhibitor in combination with an immune checkpoint inhibitor, and more specifically to treating cancer with a pyridopyrimidine derivative in combination with a PD-1 or PD-L1 inhibitor.




FIG. 1

WO 2025/188668 A1